Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 6, 2015, Pages

  Castillo, Mayret ^a   Scott, Neil W ^b   Mustafa, Mohammad Z ^c   Mustafa, Mohammed S ^d   Azuara Blanco, Augusto ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c PRINCESS ALEXANDRA EYE PAVILION   (United Kingdom)

^d Moorfields Eye Hospital Dubai   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAZOLINE PLUS TETRYZOLINE; ANTIHISTAMINIC AGENT; AZELASTINE; BEPOTASTINE; CROMOGLYCATE DISODIUM; EMEDASTINE; HISTAMINE RELEASE INHIBITOR; KETOTIFEN; LEVOCABASTINE; MEQUITAZINE; NEDOCROMIL; OLOPATADINE; PEMIROLAST; PLACEBO; ANTIALLERGIC AGENT; HISTAMINE;

BLURRED VISION; BURNING SENSATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DRY NOSE; EPIPHORA; EYE DISEASE; HUMAN; OCULAR DISCHARGE; OCULAR PRURITUS; PERENNIAL ALLERGIC CONJUNCTIVITIS; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; SIDE EFFECT; SYSTEMATIC REVIEW; TASTE DISORDER; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; CONJUNCTIVITIS, ALLERGIC; DRUG EFFECTS; MAST CELL; META ANALYSIS; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEASON; SECRETION (PROCESS);

ANTI-ALLERGIC AGENTS; CONJUNCTIVITIS, ALLERGIC; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; MAST CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEASONS;

EID: 84957793498     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009566.pub2     Document Type: Review

References (68)

1. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clinical Therapeutics 2005;27(9):1392-402.
2. Azevedo M, Castel-Branco MG, Ferraz Oliveira J, Ramos E, Delgado L, Almeida J. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in treatment of seasonal conjunctivitis. Clinical and Experimental Allergy 1991;21(6):689-94.
3. Canonica GW, Ciprandi G, Petzold U, Kolb C, Ellers-Lenz B, Hermann R. Topical azelastine in perennial allergic conjunctivitis. Current Medical Research & Opinion 2003;19(4):321-9.
4. Carr WW, Nayak AS, Ratner PH, Gow JA, McNamara TR, Williams JI, et al. Efficacy of Bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: A randomized, placebo-controlled, natural exposure, clinical trial. Allergy Asthma Proceedings 2013;34(3):247-54.
5. Davies BH, Mullins J. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Allergy 1993;48(7):519-24.
6. Fujishima H, Fukagawa K, Tanaka M, Uchio E, Takamura E, Nakagawa Y, et al. The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis. Ophthalmologica 2008;222(4):232-9.
7. Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. A double-blind, randomized, placebo-controlled study. Allergy 1998;53(9):857-62.
8. Graue E, Garcia-Valenzuela E. Double-masked study of topical levocabastine versus topical placebo in management of seasonal conjunctivitis [Estudio doble ciego de levocabastina tópica contra placebo tópico en el manejo de las conjuntivits primaverales]. Investigacion Medica Internacional 1994;21(1):35-42.
9. Hechanova M. A double-blind study comparing sodium cromoglycate eye ointment with placebo in the treatment of chronic allergic conjunctivitis. Clinical Trials Journal 1984;21(2):59-66.
10. Höffling-Lima AL, Andrade AJ, Marback PM, Farah ME, Mascaro V. Comparison between topical use of ketotifen and olopatadine in the treatment of allergic conjunctivitis [Comparação do uso tópico de cetotifeno com a olopatadina no tratamento de conjuntivites alérgicas]. Arquivos Brasileiros de Oftalmologia 2001;64(5):415-22.
11. James IG, Campbell LM, Harrison JM, Fell PJ, Ellers-Lenz B, Petzold U. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhinoconjuctivitis. Current Medical Research and Opinion 2003;19(4):313-20.
12. Katelaris CH, Ciprandi G, Missotten L, Turner FD, Bertin D, Berdeaux G, et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clinical Therapeutics 2002;24(10):1561-75.
13. Kidd M, Mckenzie SH, Steven I, Cooper C, Lanz R, Australian Ketotifen Study Group. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. British Journal of Ophthalmology 2003;87(10):1206-11.
14. Lanier BQ, Gross RD, Marks BB, Cockrum PC, Juniper EF. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Annals of Allergy, Asthma and Immunology 2001;86(6):641-8.
15. Leino M, Ennevaara K, Latvala AL, Nordgren P, Posti AM, Suves R, et al. Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clinical and Experimental Allergy 1992;22(10):929-32.
16. Lenhard G, Mivsek-Music E, Perrin-Fayolle M, Obtulowicz K, Secchi A. Double-blind, randomised, placebo-controlled study of two concentrations of azelastine eye drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Current Medical Research and Opinion 1997;14(1):21-8.
17. McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clinical Ophthalmology 2012;6:1731-8.
18. Melamed J, Schwartz RH, Hirsch SR, Cohen SH. Evaluation of nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Annals of Allergy 1994;73(1):57-66.
19. Melamed J, Schwartz RH, Blumenthal MN, Zeitz HJ. Efficacy and safety of nedocromil sodium 2% ophthalmic solution b.i.d. in the treatment of ragweed seasonal allergic conjunctivitis. Allergy and Asthma Proceedings 2000;21(4):235-9.
20. Möller C, Berg IM, Berg T, Kjellman M, Strömberg L. Nedocromil sodium 2% eye drops for twice-daily treatment of seasonal allergic conjunctivitis: a Swedish multicentre placebo-controlled study in children allergic to birch pollen. Clinical and Experimental Allergy 1994;24(9):884-7.
21. Nazarov O, Petzold U, Haase H, Nguyen DT, Ellerz-Lenz B, Hermann R. Azelastine eye drops in the treatment of perennial allergic conjunctivitis. Arzneimittel-Forschung 2003;53(3):167-73.
22. Petzold U, Blochin BM, Zimmerman T, Sabbah A, Karafilidis J, Lavallee N, et al. Efficacy and safety of azelastine in allergic conjunctivitis in children. Journal of Allergy and Clinical Immunology 2002;109(Suppl 1):162.
23. Sabbah A, Marzetto M. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Current Medical Research and Opinion 1998;14(3):161-70.
24. Sarker S, Chowdhury AN, Hussain Z, Mosharrof Hossain AK, Chowdhury H. Comparison of the therapeutic efficacy of 0.1% olopatadine hydrochloride and 0.025% ketotifen fumarate in allergic conjunctivitis. Therapy 2011;8(5):545-53.
25. Secchi A, Ciprandi G, Leonardi A, Deschenes J, Abelson MB, Emadine Study Group. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Acta Ophthalmologica Scandinavica. Supplement 2000;78:42-7.
26. Secchi A, Leonardi A, Discepola M, Deschenes J, Abelson MB, Emadine Study Group. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Acta Ophthalmologica Scandinavica. Supplement 2000;78:48-51.
27. Trinquand C, Belayachi N, Hoang-Xuan T, International Mequitazine Investigators Group. Clinical double masked comparison of Mequitazine eyedrops 0.05% compared to Levocabastine eyedrops 0.05% in allergic conjunctivitis. Investigative Ophthalmology and Visual Science 1999; Vol. 40:ARVO E-Abstract 4819.
28. Varguez-Rodriguez ME, Hernández-López RA, Gómez-Dávila R. Olopatadine and ketotifen for the treatment of allergic conjunctivitis [Olopatadina y ketotifeno para tratar conjuntivitis alérgica]. Revista Médica del Instituto Mexicano del Seguro Social 2009;47(4):399-404.
29. Verin P, Eatsy DL, Secchi A, Ciprandi G, Partouche P, Nemeth-Wasmer G, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. American Journal of Ophthalmology 2001;131(6):691-8.
30. Wertheimer R, Bleβmann G. Antazolin/tetryzolin-eyedrops in comparison to levocabastine-eyedrops in acute allergic conjunctivitis [Antazolin/tetryzolinhaltige augentropfen im vergleich zu levocabastinhaltigen augentropfen bei akuter allergischer Konjunktivitis]. Klinische Monatsblatter fur Augenheilkunde 1997;210(2):93-6.
31. Abelson MA, Ghosh P, Bradford R, Kim B, Schiffman R, Whitcup S. An environmental study of ophthalmic epinastine in patients with allergic conjunctivitis. Journal Allergy Clinical Immunology 2003;111:2.
32. Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Gross RD, Turner FD, et al. Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study. Clinical Therapeutics 2004;26(8):1237-48.
33. Artal MN, Luna JD, Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Acta Ophthalmologica Scandinavica. Supplement 2000;78:64-5.
34. Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek S. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmologica 2009;87(5):549-54.
35. Garay RP, Doucet P, Garay ER, Deschamps E, Dureau P, Baehre M, et al. Seasonal allergic conjunctivitis: a pilot study of the clinical efficacy of azelastine eye drops in comparison with nedocromil. Annals of Allergy, Asthma and Immunology 2001;86:114.
36. Higuchi M, Ohno S, Minami H, Matsuda H. Clinical trial of disodium cromoglycate and AA-344 in allergic conjunctivitis. Journal of Clinical Ophthalmology 1979;3(12):1501-4.
37. Kamis U, Ozturk BT, Ozkagnici A, Gunduz K. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis. Acta Ophthalmologica Scandinavica 2006;84(1):147-8.
38. Leino M, Montan P, Njå F. A double-blind group comparative study of ophthalmic sodium cromoglycate, 2% four times daily and 4% twice daily, in the treatment of seasonal allergic conjunctivitis. Allergy 1994;49(3):147-51.
39. Leonardi A, Zafirakis P. Efficacy and comfort of olopatadine versus ketotifen ophthalmic solutions: a double-masked, environmental study of patient preference. Current Medical Research & Opinion 2004;20(8):1167-73.
40. Longo L, Patruno D, Scaramuzzi O, Foshino Barbaro M. Sodium cromoglycate in allergic conjunctivitis. Treatment experience [Il sodiocromoglicato nella congiuntivite allergica: esperienze di trattamento]. Folia Allergologica et Immunologica Clinica 1979;26(5):425.
41. Merayo J, Montero J, Sainz de la Maza MT, Fuster E, Lladonosa A. Effectiveness and impact in the quality of life of Ketotifen ophthalmic solution. Results of Zeta study in patients with seasonal allergic conjunctivitis [Efectividad e impacto en la calidad de vida del colirio de Ketotifeno. Resultados del estudio Zeta en pacientes con conjuntivitis alérgica estacional]. Archivos de la Sociedad Española de Oftalmologia 2003;78(8):433-41.
42. Möller C, Blychert LO. Levocabastine eyedrops in comparison with cromoglycate in the treatment of conjunctivitis in children with birch pollinosis. Pediatric Allergy and Immunology 1990;1:87-9.
43. Napoli G, Allegri P, Musso C, Morchio A, Callegarini L, Murialdo U, et al. Long-term follow-up of allergic conjunctivitis in children: the outpatients' department experience (allergic conjunctivitis in children: management and care). European Annals of Allergy and Clinical Immunology 2005;37(1):21-3.
44. Pinto CG, Lafuma A, Fagnani F, Nuijten MJC, Berdeaux G. Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries. Pharmacoeconomics 2001;19(3):255-65.
45. Scadding GK, Tasman AJ, Murrieta-Aguttes M, Bachert C, The Riperex Study Group. Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis. Riperex Study Group. Journal of International Medical Research 1999;27(6):273-85.
46. Scoper S, Berdy GJ, Lichtenstein SJ, Rubin JM, Bloomenstein M, Prouty RE, et al. Perception and quality of life associated with the use of olopatadine 0.2% (Pataday) in patients with active allergic conjunctivitis. Advances in Therapy 2007;24(6):1221-32.
47. Torkildsen GL, Ousler III GW, Gomes P. Ocular comfort and drying effects of three topical antihistamine/mast cell stabilizers in adults with allergic conjunctivitis: a randomized, double-masked crossover study. Clinical Therapeutics 2008;30(7):1264-71.
48. Dharmistha P, Sarala N, Datti NP. Comparative study of topical olopatadine hcl 0.1% with ketotifen fumarate 0.025% in treatment of allergic conjunctivitis. Indian Journal of Pharmacology Conference: 46th Annual Conference of the Indian Pharmacological Society, IPSCON; 2013 Dec 16-18; Bangalore. 2013.
49. Jia HL, Liu CM, Deng HW, Han B, Zhu XL. Clinical study of Azelastine eye drops in children with allergic conjunctivitis. International Eye Science 2012; Vol. 12, issue 4:780-1.
50. Scandashree K, Patil M, Udaykumar P, Mendonca N. Comparison of efficacy and tolerability of olopatadine hydrochloride 0.2% ophthalmic solution Od and sodium cromoglycate 2% ophthalmic solution qid in allergic conjunctivitis - A randomized, open label, prospective study. Indian Journal of Pharmacology Conference: 46th Annual Conference of the Indian Pharmacological Society, IPSCON; 2013 Dec 16-18; Bangalore. 2013.
51. Abelson MB, Allansmith MR. Histamine in the eye. In: Silverstein A, O'Connor G editor(s). Immunology and Immunopathology of the Eye. New York: Masson Publishing, 1979:362-4.
52. Anderson DF. Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies. Clinical and Experimental Allergy 2001;31(6):823-6.
53. Beasley, R, The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998;351(9111):1225-32.
54. Buckley R. Allergic eye disease. In: Durham SR editor(s). ABC of Allergies. London: BMJ Books, 1998:23-5.
55. Cook EB, Stahl JL, Barney NP, Graziano FM. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Current Drug Targets. Inflammation and Allergy 2002;1(2):167-80.
56. Dart JK. Eye disease at a community health centre. British Medical Journal 1986;293(6560):1477-80.
57. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
58. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
59. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16. Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
60. Hingorani M, Lightman S. Ocular allergy. In: Kay AB editor(s). Allergy and Allergic Disease. Oxford: Blackwell Science, 1997:1645-70.
61. Leonardi A. Emerging drugs in ocular allergy. Expert Opinion on Emerging Drugs 2005;10(3):505-20.
62. Leonardi A, Motterle L, Bortolotti M. Allergy and the eye. Clinical and Experimental Immunology 2008;153(Suppl 1):17-21.
63. Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. Journal of Allergy and Clinical Immunology 2005;115(1):118-22.
64. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
65. Simons FE. Comparative pharmacology of H1 antihistamines: clinical relevance. American Journal of Medicine 2002;113(Suppl 9A):38-46.
66. Strachan D, Sibbald B, Weiland S, Aït-Khaled N, Anabwani G, Anderson HR, et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatric Allergy and Immunology 1997;8(4):161-76.
67. Whitcup SM, Cunningham ET Jr, Ng EW. Recent advances in ocular therapeutics. International Ophthalmology Clinics 2006;46(4):1-6.
68. Mustafa MS, Castillo M, Mustafa MZ, Scott N, Azuara-Blanco A. Topical antihistamines for treating seasonal and perennial allergic conjunctivitis. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD009566]